10
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The determination of release from isolation of COVID-19 patients requires ultra-high sensitivity nucleic acid test technology

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dear Editor, The prevention and control of SARS-CoV-2 has entered a critical period. Recent one paper in this journal also discussed weather qualitative RT-PCR be used to determine release from isolation of COVID-19 patients [1]. This issue is really important. Since the outbreak of COVID-19 worldwide, discontinuation of isolation has been presenting a dilemma of COVID-19, despite of the test-based strategy or the symptom-based strategy [1]. The reason for the confusion is that nucleic acid testing presents false negative based on qPCR technology, because of its low sensitivity 2, 3, 4. There are several factors for false negative, including sample collection, preservation, transportation, virus inactivation, nucleic acid extraction and technical sensitivity, among which technical sensitivity and precise sampling are the most important quality control measures to eliminate false negative. It is well known that SARS-CoV-2 nucleic acid test is the main diagnostic method of COVID-19. Recombinase polymerase amplification (RPA) is a new technology for testing nucleic acid with some advantages of simple operation, fast speed and low cost based on isothermal amplification. In our study, we developed an improved strategy, termed as nestRPA (nest recombinase polymerase amplification), which could greatly improve the sensitivity of nucleic acid detection for SARS-CoV-2 than RPA or qPCR. Firstly, we designed eight sets of primers and probes for RPA on the conservation regions of SARS-CoV-2 genes, in which some fragments were designed to span multiple gene regions (Figure 1 A) which is one of the important technical tips. Through the two rounds of primer screening, we found that the limit of detection (LOD) of 16 pairs of primers and 8 probes is quite different (Figure 1B), in which Fragment 1 against ORF1 gene had the worst amplification efficiency. And Fragment 5 and 7 had the smallest LOD value, 300 and 500 copies/uL (Figure 1C to 1F), respectively. Figure 1 Nucleic acid detection results using nestRPA. (A) The distribution of target fragments on SARS-CoV-2 genome. (B) The LOD of optimum primer pairs from different gene regions. (C) The sensitivity of outer primers for Fragment 5. (D) The sensitivity of inner primers for Fragment 5. (E) The sensitivity of outer primers for Fragment 7. (F) The sensitivity of inner primers for Fragment 7. (G) The sensitivity of nestRPA for Fragment 5. (H) The sensitivity of nestRPA for Fragment 7. (I) The five positive results of four people returning to work by nestRPA. (J) Statistics of nucleic acid detection results by nestRPA and qPCR assays for SARS-CoV-2. “*”, the statistical difference of fluorescence intensity difference between test sample and blank control serves as the criterion for judging the positive (p<0.05) of per reaction. Figure 1 As far as we know, we firstly proposed the concept of nestRPA. The basic principles of nestRPA are as follows: in nestRPA, the first amplification fragment of target gene is amplified by outer primers, then a second fragment of target gene completely within the first amplification fragment is amplified by inner primers. In order to eliminate the influence of the fluorescence signal of enzymes, fluorescent probe is not included in first RPA reaction which is another important technical tips. And in the second RPA reaction, fluorescent probe will be added into reaction system. Using nestRPA technology, we found that positive plasmid containing SARS-CoV-2 with the concentration of 1 copy/ul could also be stably detected by Fragment 5 and Fragment 7 within 1-10 minutes (Figure 1G and 1H), suggesting that nestRPA technology indeed performed very well for the detection of SARS-CoV-2 nucleic acid. In order to promote the clinical application of nestRPA technology, we firstly collected 14 samples from 14 patients diagnosed as COVID-19, all of which SARS-CoV-2 nucleic acid were positive using qPCR. The results of nestRPA assay showed that SARS-CoV-2 nucleic acid of these samples were 100% (14/14) positive. And then one positive sample (Szt_P_002) with the lowest Cq-value was selected to test the sensitivity of nestRPA technology. We found the detection result of Szt_P_002 sample was still positive after 11 times of 10-fold serial dilution by nestRPA assay, whilst after the fourth times of the same dilution fold, the result by qPCR test has been negative. Secondly, 101 samples from 73 patients diagnosed as COVID-19 were collected, all of which had negative results using qPCR, whilst 32.67% (33/101) of the samples were identified as by nestRPA assay. Furthermore, we collected 25 samples from 8 re-positive patients who repeatedly hospitalized suffering from COVID-19. Our results showed that 96.00% (24/25) of the samples tested positive by nestRPA whilst only 24.00% (6/25) of the samples were confirmed as positive by qPCR. These six samples with positive results by qPCR also had positive results by nestRPA. Our detection results were basically consistent with the clinical diagnosis results. Moreover, to explore whether there were asymptomatic patients with SARS-CoV-2 nucleic acid positive in healthy population, we collected 32 nasal swabs samples from those returning to work, all of which the SARS-CoV-2 nucleic acid detection results were negative using qPCR. However, we found 12.50% (4/32) of the samples were positive using Fragment 5 and/or Fragment 7 by nestRPA (Figure 1I), which was consistent with those reported by other researchers [5]. Our results suggested that the ultra-sensitive nucleic acid detection technique has important implications for early identification of those asymptomatic carriers infected with SARS-CoV-2. Of course, in order to avoid false positive results, the target sequence of positive amplification products was 100% detected by high-throughput sequencing. In summary, 36.18% (55/152) of the samples with qPCR negative results were identified as positive by nestRPA technology in 172 clinical samples from 127 patients, which indicated the analytical sensitivity of nestRPA assay is much better than that of qPCR (Figure 1J). In addition, many experts of COVID-19 prevention and treatment clearly pointed out that the inaccurate sample collection were also one of the important reasons for the false negative result of SARS-CoV-2 nucleic acid 6, 7, 8. The most commonly sites used as sampling are oropharynx and nasopharynx. The sample collectors should fix the tongue with a spatula, and the sampling swab is used to scrape the cells from tonsil recess and lateral wall when sampling from the oropharynx [9]. However, the sample collectors were often fear of contagion with SARS-CoV-2. Under great infection pressure, inaccurate sampling sites and inadequate sample volume will lead to false negative test results. Therefore, it is helpful to reducing the false negative through strict and normative operation of precise sampling with well protection for sample collectors (Figure 2 ). Figure 2 Comparison of clinical sampling method and a protective sampling kit with light source. (Left) Wrong sampling method; (Middle) Correct sampling method; (Right) protective sampling kit with light source. This device is a protective oral-nasopharyngeal sampling set with built-in light source, including 7 components: (1) LED inspection lamp handle; (2) LED inspection light; (3) Disposable use of anti-droplet baffle; (4) U-shaped slot; (5) Sterile swab; (6) Sampling hole; (7) Sterile tongue depressor. Figure 2 Except for the technical sensitivity and precise sampling, we also need to pay more attention for the quality control of sample preservation and transportation, virus inactivation, nucleic acid extraction [10]. If all the links in the detection of SARS-CoV-2 nucleic acid could be strictly administrated, false negative could be completely eliminated, and the discontinuation of isolation will no longer be a dilemma for us. Author Contributions All authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Jian Huang was responsible for study concept and design. Zheng Zhang and Xinchun Chen were responsible for specimens sampling. Wanqiu Huang and Dachuan Lin were responsible for the experiment and statistical analysis. Wanqiu Huang, Dachuan Lin, Cuini Wang, Chaohui Bao and Zhaoqi Zhang were responsible for the analysis of data. Wanqiu Huang and Jian Huang were responsible for drafting the manuscript. Declaration of Competing Interest No authors declared any potential conflicts of interest.

          Related collections

          Most cited references10

          • Record: found
          • Abstract: found
          • Article: not found

          Antibody Detection and Dynamic Characteristics in Patients with COVID-19

          Abstract Background The corona virus disease 2019 (COVID-19) caused by the corona virus 2 (SARS-CoV-2) has been rapidly spreading nationwide and abroad. A serologic test to identify antibody dynamics and response to SARS-CoV-2 was developed. Methods The antibodies against SARS-CoV-2 were detected by an enzyme-linked immunosorbent assay (ELISA) based on the recombinant nucleocapsid protein of SARS-CoV-2 in patients with confirmed or suspected COVID-19 at 3-40 days after symptom onset. The gold standard for COVID-19 diagnosis was nucleic acid testing for SARS-CoV-2 by RT-PCR. The serodiagnostic power of the specific IgM and IgG antibodies against SARS-CoV-2 was investigated in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and consistency rate. Results The seroconversion of specific IgM and IgG antibodies were observed as early as the 4th day after symptom onset. In the confirmed patients with COVID-19, sensitivity, specificity, PPV, NPV, and consistency rate of IgM were 77.3% (51/66), 100%, 100%, 80.0%, and 88.1%, and those of IgG were 83.3.3% (55/66), 95.0%, 94.8%, 83.8%, and 88.9 %. In patients with suspected COVID-19, sensitivity, specificity, PPV, NPV, and consistency rate of IgM were 87.5% (21/24), 100%, 100%, 95.2%, and 96.4%, and those of IgG were 70.8% (17/24), 96.6%, 85.0%, 89.1%, and 88.1%. Both antibodies performed well in serodiagnosis for COVID-19 rely on great specificity. Conclusions The antibodies against SARS-CoV-2 can be detected in the middle and later stage of the illness. Antibody detection may play an important role in the diagnosis of COVID-19 as complement approach for viral nucleid acid assays.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            False‐negative of RT‐PCR and prolonged nucleic acid conversion in COVID‐19: Rather than recurrence

            Abstract A novel coronavirus (COVID‐19) pandemic cause by Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) threatens the world. We read with interest the recent report by Li et al. that included 610 patients with Coronavirus Disease 2019 (COVID‐19). They reported a high false‐negative rate of real‐time reverse transcription polymerase chain reaction (RT‐PCR) results for SARS‐CoV‐2 detection. In addition, recent report regarding SARS‐CoV‐2 “turn positive” in recovered cases with COVID‐19 were published. Here, we studied the characteristics of nucleic acid conversion for SARS‐CoV‐2 from 70 COVID‐19 patients. We found that 15 (21.4%) patients experienced a “turn positive” of nucleic acid detection by RT‐PCR test for SARS‐CoV‐2 after two consecutive negative results, which may be related to the false negative of RT‐PCR test and prolonged nucleic acid conversion This article is protected by copyright. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Negative Nasopharyngeal and Oropharyngeal Swabs Do Not Rule Out COVID-19

              LETTER Coronavirus disease 19 (COVID-19) has become the Public Health Emergency of International Concern. A diagnosis is made by the detection of a novel virus or genetically similar coronavirus by molecular assay in clinical specimens (1). Nasopharyngeal and oropharyngeal (NP/OP) samples are commonly used as a screening tool. Here, we reported a case of COVID-19 pneumonia diagnosed from bronchoalveolar lavage (BAL) fluid that initially had negative tests from NP/OP swabs. On 21 January 2020, a 28-year-old previously healthy Chinese man presented to Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand, with a 3-day history of high-grade fever and malaise. He also complained of rhinorrhea and cough, which had already resolved. He traveled from Jinzhou, China, to Chiang Mai on 15 January 2020 by trains and airplanes, with a brief transit in Wuhan, China. After his full itinerary was identified, his case was reported to the local government health agency as a patient under investigation for COVID-19. He was admitted to an airborne infection isolation room, and NP/OP swabs were obtained. The specimens were sent to two reference laboratories (the Thai Red Cross Emerging Infectious Diseases Health Sciences Center, Faculty of Medicine, Chulalongkorn University, and the Department of Medical Sciences, Ministry of Public Health) and tested negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by a real-time reverse transcriptase PCR (RT-PCR) assay (1). His chest radiograph on hospital day 3 did not reveal any infiltration. He continued to be febrile without other respiratory symptoms. On hospital day 5, the NP/OP swabs were repeated and were again reported as negative for SARS-CoV-2. On hospital day 7, he developed nonproductive cough. The chest radiograph revealed bilateral lower lung infiltrates with prominence on the right (Fig. 1), which was compatible with viral pneumonia. Bronchoscopy and BAL were performed on hospital day 8, and BAL fluid tested positive for SARS-CoV-2 by RT-PCR. On hospital day 10, his overall clinical condition improved, with increasing appetite, and he was afebrile. He was discharged on hospital day 18. FIG 1 Chest radiographs. A posteroanterior radiograph of the chest in the upright position of the patient on hospital day 3 (A) shows no infiltration. A follow-up radiograph on hospital day 7 (B) after the patient developed nonproductive cough reveals new bilateral lower lung infiltrates, which are predominantly noticed on right lower lung zone. Our case highlighted the importance of high clinical suspicion in this epidemiologically matched patient who had negative NP/OP swabs. Although most of the reported cases have established diagnoses from NP/OP swabs, it is possible that NP/OP swabs could yield a false-negative result. Several factors might have contributed to the false-negative results, including, but not limited to, the sampling technique, transportation process, or limited gene(s) detection; however, it could also be explained by the nature of coronavirus itself. This finding was observed in previous severe acute respiratory syndrome (SARS) (2) and Middle East respiratory syndrome (MERS) (3) outbreaks. It is supported by the basic science evidence that the target functional receptor of these viruses is angiotensin-converting enzyme 2 (ACE2) (4, 5). Surface expression of ACE2 was found abundantly on both type I and type II alveolar epithelial cells but minimally on bronchial epithelial cells and negative on the nasal, oral, and nasopharynx samples. Based on this case presentation, we strongly recommend that clinicians continue to be suspicious of COVID-19 infection in an epidemiologically linked patient despite a negative NP/OP result.
                Bookmark

                Author and article information

                Contributors
                Journal
                J Infect
                J. Infect
                The Journal of Infection
                Published by Elsevier Ltd on behalf of The British Infection Association.
                0163-4453
                1532-2742
                2 July 2020
                2 July 2020
                Affiliations
                [1 ]Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Centre for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, 200240, China
                [2 ]Guangdong Key Laboratory of Regional Immunity and Diseases, Department of Pathology Biology, School of Medicine, Shenzhen University, Shenzhen, 518060, China
                [3 ]Institute of Hepatology, National clinical research center for infectious diseases, Guangdong Key Lab for Diagnosis &Treatment of Emerging Infectious Diseases, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, 518112, China
                [4 ]Department of General Surgery, Shanghai Jiao Tong University Affiliated First People's Hospital, Shanghai, 200080, China
                Author notes
                [* ]Correspondence: Prof. Jian Huang, PhD, Shanghai Centre for Systems Biomedicine, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Centre for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China jianhuang@ 123456sjtu.edu.cn
                [** ]Prof. Zheng Zhang, PhD, MD, Institute of Hepatology, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, China zhangzheng1975@ 123456aliyun.com
                Article
                S0163-4453(20)30456-4
                10.1016/j.jinf.2020.06.075
                7330563
                701e1683-2a88-4f63-8989-dd64a8880aa9
                © 2020 Published by Elsevier Ltd on behalf of The British Infection Association.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 30 June 2020
                Categories
                Article

                Infectious disease & Microbiology
                sars-cov-2,covid-19,nucleic acid detection,false negative,nestrpa

                Comments

                Comment on this article